Colorectal Cancer Treatment Concepts for Internal Me... | MDster You are offline Back online! [ ](/) Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. Colorectal Cancer Treatment Concepts: Surgery to Surveillance [ Medical Education ](https://mdster.com/blog?category=medical-education) Colorectal Cancer Treatment Concepts: Surgery to Surveillance =============================================================== A board-focused, clinically practical review of how to think about surgery, adjuvant therapy, metastatic palliation, and post-resection follow-up in colorectal cancer. [ MDster Editorial Team ](https://mdster.com/about) · Mar 29, 2026 · 6 min read · 52 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Internal Medicine ](https://mdster.com/blog?tag=internal-medicine) [ Gastrointestinal Oncology ](https://mdster.com/blog?tag=gastrointestinal-oncology) [ Colorectal Cancer ](https://mdster.com/blog?tag=colorectal-cancer) [ Oncology Boards ](https://mdster.com/blog?tag=oncology-boards) [ Cancer Surveillance ](https://mdster.com/blog?tag=cancer-surveillance) ![Colorectal Cancer Treatment Concepts: Surgery to Surveillance](https://mdster.com/storage/blog/images/colorectal-cancer-treatment-concepts-surgery-to-surveillance.jpg) Share this article Share this post A patient with newly resected pT3N1 colon adenocarcinoma is recovering well, and the intern asks, “So we just watch now?” That question captures why **treatment concepts** matter. In colorectal cancer (CRC), the key decisions after diagnosis are not semantic; they define whether you are aiming for cure, relapse reduction, or palliation. For internists, this is everyday medicine: you will manage chemotherapy toxicity, iron deficiency, ostomy complications, VTE risk, and the surveillance plan long after the operation note is signed. [\[1\]](#cite-1 "Reference [1]") Start with treatment intent --------------------------- The first treatment question is not “colon or rectum?” It is **localized, potentially curable metastatic, or unresectable metastatic**. Localized **colon** cancer is usually surgery first. **Rectal** cancer is different: MRI staging drives management, and many higher-risk stage II/III cases now receive **total neoadjuvant therapy (TNT)** before any operation; selected complete responders may even discuss nonoperative management in expert programs. Always get **MMR/MSI status** early. That is not just genetics housekeeping: it helps identify Lynch syndrome and now directly changes treatment selection in rectal and metastatic disease. [\[2\]](#cite-2 "Reference [2]") SettingUsual backboneBoard trap**Colon cancer**Surgery first, then adjuvant therapy by pathologic riskForgetting that node count matters for staging**Rectal cancer**MRI-based planning; neoadjuvant/TNT common in locally advanced diseaseTreating it like “colon cancer lower down” That split is the one boards expect you to keep straight. [\[3\]](#cite-3 "Reference [3]") Surgery and adjuvant therapy overview ------------------------------------- For **colon cancer**, oncologic resection with adequate lymphadenectomy is the backbone, and **fewer than 12 lymph nodes examined** is itself a high-risk feature because it weakens staging confidence. **Stage III colon cancer** generally gets adjuvant chemotherapy unless frailty or competing risk overwhelms benefit; common platforms are **FOLFOX** or **CAPOX**, with duration individualized to recurrence risk and oxaliplatin neurotoxicity. **Stage II** is where learners overcall treatment. Do **not** give adjuvant therapy reflexively. Offer it clearly for **T4** tumors and consider it for other high-risk features such as fewer than 12 nodes, lymphovascular or perineural invasion, poor differentiation, obstruction, perforation, or marked tumor budding. The high-yield exception is **dMMR/MSI-H stage II disease**: do not routinely reach for fluoropyrimidine monotherapy there. [\[3\]](#cite-3 "Reference [3]") Hereditary syndromes belong in this discussion, even in an overview. If Lynch syndrome, FAP, or another inherited syndrome is suspected, do not treat surgery as a one-size-fits-all event. The extent of colectomy, surveillance of the remaining bowel, and cascade testing for relatives may all change. In practice, that means the internist should not ignore a young patient, synchronous tumors, heavy family history, or universal tumor testing that shows MMR deficiency. [\[4\]](#cite-4 "Reference [4]") > **Clinical Pearl:** In stage II colon cancer, the right question is not “chemo or no chemo?” It is “**which risk features are actually present, and is the tumor dMMR/MSI-H?**” That single pause prevents a lot of board errors. [\[3\]](#cite-3 "Reference [3]") Metastatic disease: palliative does not mean passive ---------------------------------------------------- Most metastatic CRC is treated with **palliative intent**, but never confuse palliative with nihilistic. The goals are to control symptoms, preserve performance status, prolong survival, and keep future lines open. For **initially unresectable** disease, first-line therapy is usually a **doublet**, with triplet therapy reserved for select fit patients. Biology then takes over: **MSI-H/dMMR metastatic CRC** belongs in the immunotherapy lane; **left-sided, RAS wild-type, MSS/pMMR** disease often favors chemotherapy plus an **anti-EGFR** agent; **right-sided** RAS wild-type disease more often pairs chemotherapy with **anti-VEGF** therapy. In previously treated disease, know the board pairings: **BRAF V600E** disease points to **encorafenib plus cetuximab**, and **KRAS G12C** disease now has approved anti-EGFR-based targeted combinations in refractory settings. Limited liver, lung, or selected peritoneal metastases deserve multidisciplinary review because some patients can still reach **curative-intent resection or ablative therapy**. [\[5\]](#cite-5 "Reference [5]") Do not wait until the last admission to involve palliative care. ASCO’s current guidance is clear: patients with advanced cancer should have **early specialty palliative care integrated alongside active oncologic treatment**, especially when symptoms, distress, or goals-of-care uncertainty are already present. That is good oncology and good internal medicine. [\[6\]](#cite-6 "Reference [6]") Surveillance after resection concepts ------------------------------------- Surveillance after curative-intent resection is not clerical follow-up; it is part of treatment. The aim is to detect **salvageable recurrence** and **metachronous neoplasia** while the patient still has options. A common framework is front-loaded follow-up for five years: history/physical and **CEA** at regular intervals early on, periodic **CT chest/abdomen/pelvis**, and **colonoscopy at 1 year** after surgery (or after the perioperative clearing exam), then usually at **3 years** and then every **5 years** if normal. Rectal cancer may need additional local surveillance depending on surgical technique and local recurrence risk. Two exam traps matter: do **not** substitute **FIT/fecal DNA** for post-resection surveillance, and do not order routine blood panels as if they are validated recurrence tests. Keep the program purposeful. [\[7\]](#cite-7 "Reference [7]") Key Takeaways ------------- - Classify CRC by **treatment intent** first: localized, potentially curable metastatic, or unresectable metastatic. [\[2\]](#cite-2 "Reference [2]") - **Stage III colon cancer** usually gets adjuvant chemotherapy; **stage II** gets it selectively, and **dMMR/MSI-H stage II** is the classic exception. [\[3\]](#cite-3 "Reference [3]") - **Rectal cancer is not colon cancer in a tighter space**; TNT now shapes many locally advanced rectal cases. [\[2\]](#cite-2 "Reference [2]") - In metastatic disease, choose therapy by **MMR/MSI, RAS/BRAF status, sidedness, symptoms, and resectability**. [\[5\]](#cite-5 "Reference [5]") - After curative resection, remember the surveillance spine: **CEA/exam, periodic CT, colonoscopy at 1 year, then 3 years, then 5 years if normal**. [\[7\]](#cite-7 "Reference [7]") Conclusion ---------- If you remember one framework, make it this: **surgery treats the anatomy, adjuvant therapy treats microscopic risk, metastatic therapy follows tumor biology, and surveillance is active care—not an afterthought**. That mindset is high-yield for boards and safer for patients. [\[3\]](#cite-3 "Reference [3]") References (8) ------------------ 1. 1. [ National Cancer Institute. Colon Cancer Treatment (PDQ®)–Health Professional Version. ](https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol. 2024. ](https://pubmed.ncbi.nlm.nih.gov/39116386/) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ Baxter NN, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022. ](https://pubmed.ncbi.nlm.nih.gov/34936379/) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ pubmed.ncbi.nlm.nih.gov/25452455 ](https://pubmed.ncbi.nlm.nih.gov/25452455/) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ Morris VK, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023. ](https://pubmed.ncbi.nlm.nih.gov/36252154/) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ Ferrell BR, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2024. ](https://pubmed.ncbi.nlm.nih.gov/38748941/) [↩](#cite-ref-6-1 "Back to text") 7. 7. [ www.cancercareontario.ca/sites/ccocancercare/files/derivative/SurvivorshipClinicalGuidanceCRC.pdf ](https://www.cancercareontario.ca/sites/ccocancercare/files/derivative/SurvivorshipClinicalGuidanceCRC.pdf) [↩](#cite-ref-7-1 "Back to text") 8. 8. [ American Gastroenterological Association. Colonoscopy surveillance after colorectal cancer resection. ](https://gastro.org/clinical-guidance/colonoscopy-surveillance-after-colorectal-cancer-resection/) Next Turn reading into Internal Medicine performance ------------------------------------------------- - System‑based, exam‑style questions + explanations - Smarter review to reinforce weak topics - Build confidence with measurable progress [ Start practicing ](https://mdster.com/user/dashboard) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features. No commitment. Cancel anytime. [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() Related Posts ------------- [ ![Anxiety, Depression, and Breathlessness in Severe COPD/Asthma Overlap](https://mdster.com/storage/blog/images/anxiety-depression-and-breathlessness-in-severe-copdasthma-overlap.jpg) Medical Education ### Anxiety, Depression, and Breathlessness in Severe COPD/Asthma Overlap A focused Family Medicine review of anxiety, depression, and dyspnea in severe COPD/asthma overlap, with safer prescribing, breathing retraining, and board-style pitfalls. 6 min read 0 comments ](https://mdster.com/blog/anxiety-depression-and-breathlessness-in-severe-copdasthma-overlap) [ ![IBS Subtypes and Diagnosis: Rome IV, IBS-C/D, and Colonoscopy](https://mdster.com/storage/blog/images/ibs-subtypes-and-diagnosis-rome-iv-ibs-cd-and-colonoscopy.jpg) Medical Education ### IBS Subtypes and Diagnosis: Rome IV, IBS-C/D, and Colonoscopy A focused Internal Medicine review of IBS diagnosis: how to use Rome IV concepts, separate IBS-C from IBS-D and mixed IBS, and decide when colonoscopy is truly indicated. 7 min read 0 comments ](https://mdster.com/blog/ibs-subtypes-and-diagnosis-rome-iv-ibs-cd-and-colonoscopy) [ ![Congenital Hypothyroidism: Screening, Levothyroxine, Outcomes](https://mdster.com/storage/blog/images/congenital-hypothyroidism-screening-levothyroxine-outcomes.jpg) Medical Education ### Congenital Hypothyroidism: Screening, Levothyroxine, Outcomes High-yield review of congenital hypothyroidism for Pediatrics trainees, covering newborn screening pitfalls, urgent levothyroxine treatment, and developmental follow-up. 6 min read 0 comments ](https://mdster.com/blog/congenital-hypothyroidism-screening-levothyroxine-outcomes) [ ](/) Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) ### Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) ### Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) ### Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept